American Cancer Society (ACS)
Explore This IssueAugust 2022
The ACS guideline includes recommendations for surveillance of H&N cancer recurrence, screening for the early detection of second primary cancers and the assessment and management of potential physical and psychosocial long-term effects of H&N cancer and its treatment.
American Society of Clinical Oncology (ASCO)
ASCO’s most recent H&N cancer guidelines are for the management of salivary gland malignancy, chemotherapy in combination with radiotherapy for definitiveintent treatment of stage II to IVA nasopharyngeal carcinoma, and diagnosis and management of squamous cell carcinoma of unknown primary in the H&N.
National Comprehensive Cancer Network (NCCN)
NCCN noted that oral cavity, pharyngeal, and laryngeal cancers account for about 3.6% of new cancer cases in the United States. The guidelines state that treatment planning for H&N cancer “involves a multidisciplinary team of healthcare professionals with expertise in H&N surgery, radiation oncology, medical oncology, plastic and reconstructive surgery, dentistry, speech and swallowing therapy, nutrition, pathology, and diagnostic/interventional radiology, among others.”